Interatrial septal defect closure for cerebrovascular accidents: Exploring the role of various anticoagulants

Journal of Invasive Cardiology

Volumn 19, Issue 7, 2007, Pages 309-312

  Shammas, Nicolas W ^a   Dippel, Eric J ^a   Harb, Ghassan ^a   Egts, Stephanie ^a   Jerin, Michael ^b   Stoakes, Penny ^a   Byrd, Jeannette ^a   Shammas, Gail A ^a   Sharis, Peter ^a  

^a MIDWEST CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b ST AMBROSE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; ENOXAPARIN; HEPARIN; HIRULOG; THROMBIN INHIBITOR; TICLOPIDINE; WARFARIN;

ADULT; AGE DISTRIBUTION; AMPLATZER OCCLUDER DEVICE; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM SEPTUM DEFECT; HEART EJECTION FRACTION; HEMATOMA; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMPLANT; MAJOR CLINICAL STUDY; MALE; SEX RATIO; SMOKING; STATISTICAL SIGNIFICANCE; SURGICAL EQUIPMENT; TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; ANTITHROMBINS; CARDIAC SURGICAL PROCEDURES; CEREBROVASCULAR ACCIDENT; ENOXAPARIN; FEMALE; FOLLOW-UP STUDIES; HEART SEPTAL DEFECTS, ATRIAL; HIRUDINS; HUMANS; INCIDENCE; INTRAOPERATIVE COMPLICATIONS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34447274217     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Wahl A, Meier B, Haxel B, et al. Prognosis after percutaneous closure of patent foramen ovale for paradoxical embolism. Neurology 2001;9:57:7.
2. Rodriguez CJ, Homma S. Management of patients with stroke and a patent foramen ovale. Curr Neurol Neurosci Rep 2004;4:19-22.
3. Danzi GB, Sesanaa M, Capuano C, Baglini R. Percutaneous closure of patent foramen ovale: Pathophysiology, indications, and technique. Neurol Sci 2003;24(Suppl 1):S17-S19.
4. Onorato E, Melzi G, Casilli F, et al. Patent foramen ovale with paradoxical embolism: Mid-term results of transcatheter closure in 256 patients. J Interv Cardiol 2003;16:43-50.
5. Martin F, Sanchez PL, Doherty E, et al. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation 2002;106:1121-1126.
6. Braun MU, Fassbender D, Schoen SP, et al. Transcatheter closure of patent foramen ovale in patients with cerebral ischemia. J Am Coll Cardiol 2002;39:2019-2025.
7. Butera G, Bini MR, Chessa M, et al. Transcatheter closure of patent foramen ovale in patients with cryptogenic stroke. Ital Heart J 2001;2:114-118.
8. Shammas NW. Bivalirudin: A review of pharmacology and clinical applications. Cardiovasc Drug Rev 2005;23:345-360.
9. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the bivalirudin angioplasty study . Am Heart J 2001;142:952-959.
10. Lincoff AM, Bittl JA, Kleiman NS, et al. REPLACE-1. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial. Am J Cardiol 2004;93:1092-1096.
11. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa during percutaneous coronary intervention: The REPLACE-2 randomized trial. JAMA 2003;289:853-863.
12. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: Principal results of a meta-analysis based on individual patients' data. Lancet 2002;359:294-302.
13. Bedard E, Rodes-Cabau J, Houde C, et al. Enhanced thrombogenesis but not platelet activation is associated with transcatheter closure of patent foramen ovale in patients with cryptogenic stroke. Stroke 2007;38:100-104.